Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of “Hold” by Analysts

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONSGet Rating) have been assigned an average rating of “Hold” from the eleven ratings firms that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $42.28.

A number of brokerages have issued reports on IONS. Citigroup began coverage on Ionis Pharmaceuticals in a research note on Monday, February 28th. They set a “sell” rating and a $26.00 price target for the company. Bank of America lowered Ionis Pharmaceuticals from a “buy” rating to an “underperform” rating and decreased their price target for the company from $40.00 to $30.00 in a research note on Tuesday, February 1st. Guggenheim began coverage on Ionis Pharmaceuticals in a research note on Tuesday, March 1st. They set a “buy” rating and a $64.00 price target for the company. SVB Leerink decreased their price target on Ionis Pharmaceuticals from $29.00 to $26.00 and set a “market perform” rating for the company in a research note on Friday, April 1st. Finally, StockNews.com began coverage on Ionis Pharmaceuticals in a research note on Thursday, March 31st. They set a “hold” rating for the company.

Several institutional investors and hedge funds have recently added to or reduced their stakes in IONS. Assenagon Asset Management S.A. purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter valued at $202,000. Kestra Advisory Services LLC lifted its holdings in shares of Ionis Pharmaceuticals by 22.2% in the third quarter. Kestra Advisory Services LLC now owns 27,924 shares of the company’s stock valued at $937,000 after purchasing an additional 5,078 shares in the last quarter. Virginia Retirement Systems ET AL purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter worth $392,000. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Ionis Pharmaceuticals by 30.8% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 685,660 shares of the company’s stock worth $22,997,000 after acquiring an additional 161,334 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D raised its holdings in shares of Ionis Pharmaceuticals by 0.5% during the third quarter. State of New Jersey Common Pension Fund D now owns 87,216 shares of the company’s stock worth $2,925,000 after acquiring an additional 471 shares in the last quarter. Institutional investors own 83.97% of the company’s stock.

Shares of IONS stock opened at $40.64 on Thursday. Ionis Pharmaceuticals has a 12-month low of $25.04 and a 12-month high of $44.10. The firm has a market capitalization of $5.76 billion, a price-to-earnings ratio of -106.95 and a beta of 0.83. The business has a 50 day simple moving average of $34.68 and a 200 day simple moving average of $32.63. The company has a debt-to-equity ratio of 1.62, a current ratio of 9.75 and a quick ratio of 9.65.

Ionis Pharmaceuticals (NASDAQ:IONSGet Rating) last issued its quarterly earnings data on Thursday, February 24th. The company reported $1.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.80 by $0.61. Ionis Pharmaceuticals had a negative return on equity of 4.37% and a negative net margin of 3.45%. The business had revenue of $440.00 million during the quarter, compared to analyst estimates of $284.08 million. During the same period in the prior year, the company posted ($2.44) EPS. The business’s revenue for the quarter was up 51.7% compared to the same quarter last year. On average, equities analysts anticipate that Ionis Pharmaceuticals will post -2.39 EPS for the current fiscal year.

Ionis Pharmaceuticals Company Profile (Get Rating)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.

Featured Articles

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.